I. Elalamy

发表

Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis

X. Leleu, T. Facon, G. Fouquet, 2012, Expert review of hematology.

A novel homozygous splice junction mutation in GPIIb associated with alternative splicing, nonsense‐mediated decay of GPIIb‐mRNA, and type II Glanzmann's thrombasthenia

R. Favier, I. Elalamy, C. González-Manchón, 2003, Journal of thrombosis and haemostasis : JTH.

Thrombolytic Therapy

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Periprocedural Management of Antithrombotic Therapy and Use of Bridging Anticoagulation

G. Raskob, A. Nicolaides, M. Griffin, 2008, International Angiology.

Original Article: Streptokinase Modifies in Vitro Platelet Aggregation by Two Mechanisms: Reduced Aggregation due to Fibrinogenolysis and Enhanced Aggregation via an Immunological Reaction.

G. Helft, M. Samama, T. Lecompte, 1995, Platelets.

Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis

W. Ageno, H. Büller, T. Baglin, 2013, Journal of thrombosis and haemostasis : JTH.

How Well do European Patients Understand Cancer-Associated Thrombosis? A Patient Survey

M. Monreal, A. Falanga, J. Easaw, 2021 .

Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill

J. Douketis, R. Hull, D. Imberti, 2019, Thrombosis Journal.

Physicians’ decision about long-term thromboprophylaxis in cancer outpatients: CAT AXIS, a case vignette study on clinical practice in France

F. Scotté, G. Meyer, I. Elalamy, 2018, Supportive Care in Cancer.

Procoagulant microparticles derived from cancer cells have determinant role in the hypercoagulable state associated with cancer.

A. Larsen, I. Elalamy, G. Gerotziafas, 2017, International journal of oncology.

Differential contribution of tissue factor and Factor XII to thrombin generation triggered by breast and pancreatic cancer cells.

A. Larsen, M. Sabbah, I. Elalamy, 2017, International journal of oncology.

Thrombosis and kidney disease in cancer: comorbidities defining a very high risk patient: A position paper from the Cancer & the Kidney International Network

P. McFarlane, H. Riess, F. Scotté, 2018, Journal of Onco-Nephrology.

The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles

M. Maier‐Redelsperger, R. Girot, F. Lionnet, 2012, Thrombosis and Haemostasis.

Pathogenic heparin‐induced thrombocytopenia and thrombosis (HIT) antibodies determined by rapid functional flow cytometry

S. Kay, V. Deutsch, I. Elalamy, 2019, European journal of haematology.

Heparin-induced multiple electrode aggregometry is a promising and useful functional tool for heparin-induced thrombocytopenia diagnosis: Confirmation in a prospective study

I. Elalamy, G. Gerotziafas, A. Khaterchi, 2013, Platelets.

Heparin-Induced Thrombocytopenia

G. Raskob, A. Nicolaides, M. Griffin, 2013, Thrombosis and Haemostasis.

Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability

J. Daoud, M. Frikha, J. Gligorov, 2014, BMC Cancer.

Differential influence of breast cancer stage , time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability

J. Daoud, M. Frikha, J. Gligorov, 2014 .

The study of the thrombin generation mechanism and the effect of low molecular weight heparin as thromboprophylaxis in patients undergoing total knee and hip replacement.

C. Ioannou, P. Katonis, I. Elalamy, 2013, Thrombosis research.

Effect of two oral doses of 17β‐estradiol associated with dydrogesterone on thrombin generation in healthy menopausal women: a randomized double‐blind placebo‐controlled study

F. Zannad, A. Rousseau, T. Simon, 2009, Fundamental & clinical pharmacology.

Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin

M. Samama, I. Elalamy, G. Gerotziafas, 2009, Thrombosis and Haemostasis.

In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide.

M. Samama, I. Elalamy, F. Rendu, 2008, Thrombosis research.

Treatment for Patients With Cancer

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Treatment of Cancer-Associated Thrombosis: Beyond HOKUSAI

P. Girard, I. Mahé, I. Elalamy, 2019, TH Open.

Long‐term treatment of cancer‐associated thrombosis: the choice of the optimal anticoagulant

W. Ageno, G. Meyer, I. Mahé, 2017, Journal of thrombosis and haemostasis : JTH.

Diagnosis and Anticoagulant Treatment *

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Key Questions to be Answered

G. Raskob, A. Nicolaides, M. Griffin, 2013 .

2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group.

D. Farge, H. Lévesque, G. Meyer, 2010, Critical reviews in oncology/hematology.

SOR guidelines for the treatment of venous thromboembolism in patients with cancer : Report from the working group

D. Farge, H. Lévesque, G. Meyer, 2009 .

Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer?

P. Meria, D. Farge, M. Marty, 2008, Supportive Care in Cancer.

Standards, Options : Recommandations 2008 Traitement curatif de la maladie thromboembolique veineuse, prévention et traitement des thromboses veineuses sur cathéter chez les patients atteints de cancer

I. Elalamy, H. Desmurs-Clavel, I. Quéré, 2008 .

[2008 Standards, Options: recommendations for venous thromboembolic events (VTE) treatment and central venous catheter thrombosis (CVCT) management in cancer patients].

H. Lévesque, G. Meyer, P. Mismetti, 2008, Bulletin du cancer.

Description of Response to Aspirin and Clopidogrel in Outpatients With Coronary Artery Disease Using Multiple Electrode Impedance Aggregometry

I. Elalamy, G. Gerotziafas, M. Chaari, 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

In vitro aspirin resistance detected by PFA‐100TM closure time: pivotal role of plasma von Willebrand factor

M. Samama, I. Elalamy, G. Gerotziafas, 2004, British journal of haematology.

Real-Life Peak and Trough Dabigatran Plasma Measurements Over Time in Hospitalized Geriatric Patients with Atrial Fibrillation

O. Hanon, J. Vidal, C. Boully, 2018, The journal of nutrition, health & aging.

Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban.

M. Samama, I. Elalamy, G. Gerotziafas, 2012, Thrombosis research.

2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group.

D. Farge, H. Lévesque, G. Meyer, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies

D. Hoppensteadt, J. Fareed, E. Adjambri, 2018, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood

F. Depasse, M. Samama, I. Elalamy, 2004, Thrombosis and Haemostasis.

Human Anti-Streptokinase Antibodies Induce Platelet Aggregation in an Fc Receptor (CD32) Dependent Manner

G. Helft, M. Samama, T. Lecompte, 1995, Thrombosis and Haemostasis.

Characterization of the Antithrombotic Fingerprint of the Branded and Copies of the Low-Molecular-Weight Enoxaparin Using Thrombin Generation Assay

J. Fareed, I. Elalamy, E. Mbemba, 2015, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Effect of the anti‐factor Xa and anti‐factor IIa activities of low‐molecular‐weight heparins upon the phases of thrombin generation

M. Samama, I. Elalamy, G. Gerotziafas, 2007, Journal of thrombosis and haemostasis : JTH.

In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban

F. Depasse, E. Perzborn, I. Elalamy, 2007, Journal of thrombosis and haemostasis : JTH.

Comparison of antithrombin‐dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots

D. Cokkinos, A. Larsen, I. Elalamy, 2018, Research and practice in thrombosis and haemostasis.

Heparin‐induced multi‐electrode aggregometry method for heparin‐induced thrombocytopenia testing: communication from the SSC of the ISTH

M. Morel-Kopp, C. Ward, T. Bakchoul, 2016, Journal of thrombosis and haemostasis : JTH.

The role of platelet factor 4 in platelet aggregation induced by the antibodies implicated in heparin-induced thrombocytopenia

M. Samama, T. Lecompte, I. Elalamy, 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Platelet aggregation by IgG anti-streptokinase and anisoylated plasminogen-streptokinase activator complex: heterogenous responses in platelet-rich plasma but not in washed platelets.

M. Samama, I. Elalamy, M. Abdelouahed, 1997, Thrombosis research.

Does Lipid Profile Affect Thrombin Generation During Ramadan Fasting in Patients With Cardiovascular Risks?

I. Elalamy, M. Hassine, F. Addad, 2017, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Generic and Branded Enoxaparin Bioequivalence: A Clinical andExperimental Study

I. Elalamy, G. Gerotziafas, M. Hassine, 2015 .

Inferior Vena Cava Filters

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutation.

M. Samama, I. Gouin-Thibault, I. Elalamy, 2002, Thrombosis research.

Quelle place pour l’aspirine en prophylaxie antithrombotique veineuse ?

I. Elalamy, M. Hatmi, 2002 .

Signal transduction in the platelet activation induced by IgG anti-streptokinase and anisoylated plasminogen-streptokinase activator complex.

I. Elalamy, M. Abdelouahed, M. Hatmi, 1997, Platelets.

The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1

A. Larsen, I. Elalamy, E. Mbemba, 2017, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

On the mechanism of inhibition of tissue factor pathway by the synthetic pentasaccharide during coagulation of human plasma

F. Depasse, M. Samama, I. Elalamy, 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Lobectomy and postoperative thromboprophylaxis with enoxaparin improve blood hypercoagulability in patients with localized primary lung adenocarcinoma.

F. Bonnet, E. Marret, I. Elalamy, 2013, Thrombosis research.

Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study

M. Dimopoulos, T. Psaltopoulou, E. Kastritis, 2018, Blood Cancer Journal.

Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: External validation of the IMPEDE VTE score

X. Leleu, I. Elalamy, B. Tardy, 2020, American journal of hematology.

Assessment of the performances of AcuStar HIT and the combination with heparin-induced multiple electrode aggregometry: a retrospective study.

J. Dogné, B. Châtelain, I. Elalamy, 2013, Thrombosis research.

Platelet microparticle generation assay: a valuable test for immune heparin-induced thrombocytopenia diagnosis.

J. Dogné, B. Châtelain, I. Elalamy, 2014, Thrombosis research.

Hematological findings and complications of COVID‐19

Theodora Psaltopoulou, M. Dimopoulos, T. Psaltopoulou, 2020, American journal of hematology.

Persisting Endothelial Cell Activation and Hypercoagulability after COVID-19 Recovery—The Prospective Observational ROADMAP-Post COVID-19 Study

M. Dimopoulos, E. Terpos, M. Sabbah, 2022, Hemato.

Risk factors for unfavorable clinical outcome in patients with documented heparin-induced thrombocytopenia.

Y. Gruel, P. Nguyên, E. de Maistre, 2009, Thrombosis research.

Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism

K. Huber, N. Danchin, E. Wiel, 2013, International Journal of Emergency Medicine.

Venous thrombosis in pregnant women: genetic and epigenetic risk factors

I. Elalamy, 2019, Obstetrics, Gynecology and Reproduction.

Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies: report of 12 cases

A. Bauters, M. Wolf, P. Ffrench, 2009, Intensive Care Medicine.

European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis.

P. Kolh, A. Nicolaides, F. Vermassen, 2020, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

COVID-19, septic shock and syndrome of disseminated intravascular coagulation syndrome. Part 1

V. N. Serov, J. Gris, A. Makatsariya, 2020, Annals of the Russian academy of medical sciences.

COVID-19, neutrophil extracellular traps and vascular complications in obstetric practice

J. Gris, A. Makatsariya, J. Khizroeva, 2020, Journal of perinatal medicine.

Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study

M. Dimopoulos, E. Terpos, A. Falanga, 2022, Hemato.

Clinical Aspects and Laboratory Problems in Hereditary Thrombophilia

M. Samama, M. Horellou, I. Elalamy, 1999, Pathophysiology of Haemostasis and Thrombosis.

Absence of In Vitro Cross-Reaction of Pentasaccharide with the Plasma Heparin-Dependent Factor of Twenty-Five Patients with Heparin-Associated Thrombocytopenia

M. Samama, I. Elalamy, J. Marie, 1995, Thrombosis and Haemostasis.

Screening for aspirin resistance in stable coronary artery patients by three different tests.

M. Samama, I. Elalamy, H. Gamra, 2007, Thrombosis research.

Étude de la variabilité de réponse à l ’ aspirine et au clopidogrel : résistance clinique et / ou biologique ? Study of variability in response to aspirin and clopidogrel : Clinical and / or biological resistance ?

M. Samama, I. Elalamy, M.-M. Samamaa, 2009 .

Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin.

P. Morange, Y. Gruel, E. de Maistre, 2006, Blood.

Prospective Evaluation of a Rapid Functional Assay for Heparin-Induced Thrombocytopenia Diagnosis in Critically Ill Patients*

P. Lévy, I. Elalamy, A. Khaterchi, 2019, Critical care medicine.

Heparin-Induced Thrombocytopenia: An Estimate of the Average Cost in the Hospital Setting in France

F. Chapuis, G. Le Gal, C. Emery, 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Comparative Analysis of a French Prospective Series of 144 Patients with Heparin-Induced Thrombocytopenia (FRIGTIH) and the Literature

B. Giraudeau, V. Gouilleux-Gruart, E. de Raucourt, 2020, Thrombosis and Haemostasis.

Biochemistry and clinical pharmacology of new anticoagulant agents

M. Samama, M. Horellou, I. Elalamy, 2002, Pathophysiology of Haemostasis and Thrombosis.

EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer

S. Szmit, A. Falanga, H. ten Cate, 2022, HemaSphere.

Thrombotic and Hemorrhagic Issues Associated with Myeloproliferative Neoplasms

I. Elalamy, G. Gerotziafas, P. Vandreden, 2022, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients

I. Mahé, I. Elalamy, G. Gerotziafas, 2014, Therapeutics and clinical risk management.

Anticoagulants in frail patients. Seven situations at risk.

O. Hanon, G. Deray, V. Launay-Vacher, 2018, Journal de medecine vasculaire.

Superficial Vein Thrombosis

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Heparin‐induced multiple electrode aggregometry: a potential tool for improvement of heparin‐induced thrombocytopenia diagnosis

I. Elalamy, G. Gerotziafas, M. Hatmi, 2009, Journal of thrombosis and haemostasis : JTH.

New antithrombotic agents in cancer patients

I. Elalamy, G. Gerotziafas, M. Samama, 2012 .

The Problem and the Need for Prevention

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa

D. Hoppensteadt, J. Fareed, I. Elalamy, 2020, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Meeting Report EuroG20 Meeting on Cancer-Associated Thrombosis (CAT) Bergamo, Italy 7 April 2016

A. Falanga, I. Elalamy, 2018, Cancer investigation.

Prevention and treatment of cancer-associated thrombosis in France: A national survey among vascular disease and supportive care specialists.

A. Lamblin, F. Scotté, G. Pernod, 2017, Journal de medecine vasculaire.

Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin.

A. Larsen, I. Elalamy, E. Mbemba, 2015, Thrombosis research.

[The usefulness of platelet function evaluation in clinical practice].

I. Elalamy, G. Gerotziafas, M. Hatmi, 2013, Annales de biologie clinique.

Inhibition by eicosapentaenoic acid of IL-1beta-induced PGHS-2 expression in human microvascular endothelial cells: involvement of lipoxygenase-derived metabolites and p38 MAPK pathway.

C. Werts, I. Elalamy, J. Couétil, 2003, Biochimica et biophysica acta.

Updated clinical models for VTE prediction in hospitalized medical patients.

I. Elalamy, G. Gerotziafas, Stella Salta, 2018, Thrombosis research.

Risk of thrombosis in patients homozygous for factor V Leiden.

M. Trossaërt, I. Elalamy, J. Conard, 1995, Blood.

Pregnancy‐associated venous thromboembolism (VTE) in combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210 A mutation and in heterozygous FII single gene mutation alone

M. Samama, M. Horellou, I. Elalamy, 2003, British journal of haematology.

Heritable Thrombophilia and Pregnancy Associated Thrombosis.

M. Samama, M. Horellou, I. Elalamy, 2002, Turkish journal of haematology : official journal of Turkish Society of Haematology.

Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives

H. Abdel-Razeq, G. Agnelli, A. Falanga, 2021, TH Open.

Heparin‐induced thrombocytopenia: Construction of a pretest diagnostic score derived from the analysis of a prospective multinational database, with internal validation

P. Morange, Y. Gruel, P. Nguyên, 2021, Journal of thrombosis and haemostasis : JTH.

Platelet microparticle generation assay

J. Dogné, B. Châtelain, I. Elalamy, 2013 .

Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial

P. Verhamme, I. Ahrens, H. Darius, 2019, Thrombosis and Haemostasis.

Gynecology and Obstetrics

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Platelet glycoprotein IIIa (platelet antigen 1/platelet antigen 2) polymorphism and 1-year outcome in patients with stable coronary artery disease

I. Elalamy, Z. Dridi, H. Gamra, 2010, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Prevention of Postthrombotic Syndrome

G. Raskob, A. Nicolaides, M. Griffin, 2013 .

Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era

Shi Chen, Yiming Wang, I. Elalamy, 2020, Thrombosis Research.

COVID-19, hemostasis disorders and risk of thrombotic complications

J. Gris, E. Grandone, S. Schulman, 2020, Annals of the Russian academy of medical sciences.

Cellular source of human platelet secretory phospholipase A2

B. Vargaftig, I. Elalamy, M. Mirshahi, 1998, British journal of haematology.

Reticulated platelets: a reliable measure to reduce prophylactic platelet transfusions after intensive chemotherapy

N. Casadevall, O. Legrand, I. Elalamy, 2005, Transfusion.

Can heparin‐induced thrombocytopenia be associated with fondaparinux use? A rebuttal

B. Tribout, I. Elalamy, 2008, Journal of thrombosis and haemostasis : JTH.

Comparison of activated clotting times to heparin management test for adequacy of heparin anticoagulation in percutaneous transluminal coronary angioplasty.

G. Helft, F. Beygui, M. Samama, 1998, Catheterization and cardiovascular diagnosis.

Extracellular vesicles derived from pancreatic cancer cells BXPC3 or breast cancer cells MCF7 induce a permanent procoagulant shift to endothelial cells.

A. Larsen, I. Elalamy, G. Gerotziafas, 2019, Thrombosis research.

JAK2V617F mutation is not associated with unexplained recurrent arterial and venous thrombosis.

D. Sène, P. Cacoub, I. Elalamy, 2008, Thrombosis research.

Reversible inhibition by protamine of human synovial and rabbit platelet secretory phospholipase A2.

B. Vargaftig, I. Elalamy, S. Emadi, 1996, Biochimica et biophysica acta.

Clopidogrel but not Aspirin prevents acute smoking-induced platelet aggregation in patients with stable coronary artery disease.

I. Elalamy, H. Gamra, M. Hassine, 2009, Thrombosis research.

D-dimer levels, constitutional thrombophilia, and venous thrombosis prediction: clinical aspects and implications.

M. Horellou, I. Elalamy, J. Conard, 2005, Seminars in vascular medicine.

Apixaban Prophylactic Anticoagulation in Patients with Nephrotic Syndrome

K. Dahan, J. Boffa, I. Elalamy, 2021, TH open : companion journal to thrombosis and haemostasis.

Heparin-induced skin necrosis: HIT-2 without thrombocytopenia

J. Bazin, J. Constantin, S. Perbet, 2010, Intensive Care Medicine.

Transplantation Outcome in Recipients Engrafted With Organs Recovered From the First French Deceased Donor With a SARS-COV-2 Vaccine-Induced Thrombotic Thrombocytopenia.

M. Delahousse, F. Conti, A. Hertig, 2021, Transplantation.

Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines of Pulmonary Embolism Pulmonary Vascular Disease, of Pulmonary Embolism Deep Vein Thrombosis,

P. Liu, Yaolong Chen, I. Elalamy, 2020 .

Modelization of Blood-Borne Hypercoagulability in Myeloma: A Tissue-Factor-Bearing Microparticle-Driven Process

M. Dimopoulos, M. Mohty, A. Larsen, 2019, TH Open.

[Post partum acquired hemophilia A with fatal outcome: a case report].

I. Elalamy, G. Gerotziafas, C. Kallel, 2012, Annales de biologie clinique.

[Acquired hemophilia A in prepartum: case report and literature review].

I. Elalamy, G. Gerotziafas, M. Chaari, 2012, La Revue de medecine interne.

Early-access programme in emergency care: idarucizumab use for rapid dabigatran reversal in critical care patients.

K. Tazarourte, I. Elalamy, F. Gruenenfelder, 2019, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

Antidotes for direct oral anticoagulants

I. Elalamy, 2016 .

Critical Care Medical Patients

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis.

[2008 Standards, Options: Recommendations for venous thromboembolic events(VTE)treatment and central venous catheter thrombosis(CVCT) management in cancer patients].

H. Lévesque, G. Meyer, P. Mismetti, 2008, Journal des maladies vasculaires.

[Standards, Options: recommendations 2008; thromboembolic events treatment, prophylaxis and treatment of central venous catheter thrombosis in patients with cancer].

H. Lévesque, G. Meyer, P. Mismetti, 2008, Annales Francaise d'Anesthesie et de Reanimation.

Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease

M. Samama, I. Elalamy, Z. Dridi, 2009, Journal of Thrombosis and Thrombolysis.

Endothelial Cell Activation and Thrombin Generation Assessment for the Risk of Severe Early Onset Preeclampsia. the ROADMAP-EOP Study

I. Elalamy, G. Gerotziafas, A. Rousseau, 2022, Clinical and Applied Thrombosis/Hemostasis.

Thrombotic microangiopathy, DIC-syndrome and COVID-19: link with pregnancy prothrombotic state

J. Gris, E. Grandone, A. Makatsariya, 2020, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19: The COMPASS-COVID-19 Prospective Observational Cohort Study

M. Dimopoulos, T. Psaltopoulou, E. Terpos, 2020 .

TNF‐α, inefficient by itself, potentiates IL‐1β‐induced PGHS‐2 expression in human pulmonary microvascular endothelial cells: requirement of NF‐κB and p38 MAPK pathways

C. Werts, I. Elalamy, J. Couétil, 2002 .

Heparin-induced thrombocytopenia: laboratory diagnosis and management.

I. Elalamy, J. Conard, C. Lecrubier, 2000, Annals of medicine.

Circulating platelet-leukocyte aggregates: a marker of microvascular injury in diabetic patients.

M. Samama, F. Elgrably, I. Elalamy, 2008, Thrombosis research.

Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7.

J. Bernaudin, I. Elalamy, E. Mbemba, 2012, Thrombosis research.

Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice?

S. Laporte, X. Leleu, C. Chapelle, 2016, Thrombosis research.

Title Page / Table of Contents / Preface

F. Sofi, R. Abbate, P. Morange, 2003, Pathophysiology of Haemostasis and Thrombosis.

Heparin-induced thrombocytopenia: A complex clinical and laboratory paradox requiring multidisciplinary management

F. Donati, P. Drolet, J. Hardy, 2009 .

Graft Product for Autologous Peripheral Blood Stem Cell Transplantation Enhances Thrombin Generation and Expresses Procoagulant Microparticles and Tissue Factor

V. Vanneaux, J. Larghero, J. Lotz, 2018, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Impact of blood hypercoagulability on in vitro fertilization outcomes: a prospective longitudinal observational study

A. Larsen, E. Mathieu d'Argent, I. Elalamy, 2017, Thrombosis Journal.

Towards a standardization of thrombin generation assessment: The influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay

F. Depasse, M. Samama, I. Elalamy, 2005, Thrombosis journal.

The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation

F. Depasse, M. Samama, I. Elalamy, 2004, Thrombosis and Haemostasis.

Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine

Noor A. Jatoi, D. Šuput, M. Dimopoulos, 2020, Thrombosis and Haemostasis.

Patients With Cancer

S. Kakkos, P. Prandoni, G. Raskob, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Chapter 30 Maternal and fetal issues in COVID-19-mediated thromboinflammation

J. Gris, A. Makatsariya, I. Elalamy, 2023, Autoimmunity, COVID-19, Post-COVID19 Syndrome and COVID-19 Vaccination.

The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper

Yiannis A. Theodorou, J. Douketis, M. Dimopoulos, 2021, Thrombosis and Haemostasis.

The influence of fibrin polymerization and platelet-mediated contractile forces on citrated whole blood thromboelastography profile

M. Samama, I. Elalamy, G. Gerotziafas, 2006, Thrombosis and Haemostasis.

Thrombotic microangiopathy in cancer patients

A. Makatsariya, J. Khizroeva, I. Elalamy, 2019, Annals of the Russian academy of medical sciences.

Inhibition by Extracellular cAMP of Phorbol 12-Myristate 13-Acetate-induced Prostaglandin H Synthase-2 Expression in Human Pulmonary Microvascular Endothelial Cells

M. Singer, I. Elalamy, M. Hatmi, 2000, The Journal of Biological Chemistry.

Prevention and Treatment of Venous Thromboembolism

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Venous thrombosis risk factors in pregnant women.

J. Khizroeva, I. Elalamy, V. Bitsadze, 2020, Journal of perinatal medicine.

Evidence for cAMP-dependent Platelet Ectoprotein Kinase Activity That Phosphorylates Platelet Glycoprotein IV (CD36)*

B. Vargaftig, I. Elalamy, C. Jacquemin, 1996, The Journal of Biological Chemistry.

Inhibition of clot formation process by treatment with the lowmolecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting - A thromboelastography study on whole blood

I. Elalamy, T. Gerasimidis, G. Gerotziafas, 2006, Thrombosis and Haemostasis.

In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile

M. Samama, I. Elalamy, G. Gerotziafas, 2004, Thrombosis and Haemostasis.

Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in at-risk patient groups: pregnancy, elderly and obese patients

J. Douketis, R. Hull, D. Imberti, 2019, Thrombosis Journal.

Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines

Yaolong Chen, P. Liu, I. Elalamy, 2020, Thrombosis and Haemostasis.

Cryofibrinogenemia: new insights into clinical and pathogenic features.

D. Sène, P. Cacoub, D. Saadoun, 2009, The American journal of medicine.

Non-criteria manifestations in primary antiphospholipid syndrome: a French multicenter retrospective cohort study

J. Boffa, S. Alamowitch, A. Mékinian, 2022, Arthritis Research & Therapy.

Orthopedic Surgery and Trauma

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Clinical Studies with Anticoagulants to Improve Survival in Cancer Patients

Mohamed Hatmi, M. Samama, I. Elalamy, 2007, Pathophysiology of Haemostasis and Thrombosis.

Endothelial cell markers' kinetics following umbilical cord blood transplantation

J. Soria, I. Elalamy, F. Rendu, 2008, Leukemia & lymphoma.

MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs

O. Decaux, A. Lamblin, P. Moreau, 2013, Thrombosis and Haemostasis.

Overview of risk assessment models for venous thromboembolism in ambulatory patients with cancer.

K. Syrigos, A. Taher, I. Mahé, 2020, Thrombosis research.

[Recommendations for venous thromboembolic events treatment and central venous catheter thrombosis management in cancer patients].

H. Lévesque, G. Meyer, P. Mismetti, 2009, Presse medicale.

Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation.

I. Elalamy, G. Nguyen, J. Sraer, 2000, Blood.

A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS–Cancer‐Associated Thrombosis Study

H. Abdel-Razeq, A. Taher, A. Larsen, 2017, The oncologist.

Comparative Effects of Recombinant Staphylokinase and Streptokinase on Platelet Aggregation

G. Helft, I. Elalamy, M. Abdelouahed, 1997, Thrombosis and Haemostasis.

The COMPASS-COVID-19-ICU Study: Identification of Factors to Predict the Risk of Intubation and Mortality in Patients with Severe COVID-19

M. Dimopoulos, E. Terpos, A. Falanga, 2022, Hemato.

Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at 3-month follow-up

Shi Chen, Yiming Wang, I. Elalamy, 2021, European Respiratory Journal.

Treatment and Prevention of Cancer-Associated Thrombosis in Frail Patients: Tailored Management

F. Scotté, I. Elalamy, V. Benatar, 2019, Cancers.

General, Vascular, Bariatric, and Plastic Surgical Patients

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis.

Diagnosis and clinical characteristics of inherited activated protein C resistance.

M. Trossaërt, I. Elalamy, J. Conard, 1996, Haemostasis.

Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes

I. Elalamy, Z. Dridi, H. Gamra, 2010, International journal of hematology.

Prevention and treatment of venous thromboembolism--International Consensus Statement.

P Prandoni, G D Lowe, D Bergqvist, 2013, International angiology : a journal of the International Union of Angiology.

Combined Vaccination Approaches for COVID-19. Will These Improve the Efficacy Spectrum?

J. Fareed, I. Elalamy, G. Gerotziafas, 2021, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.

K. Syrigos, A. Falanga, A. Larsen, 2018, The oncologist.

SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia

W. Ageno, D. Jiménez, S. Middeldorp, 2021, Thrombosis and Haemostasis.

SARS-CoV-2 vaccine and thrombosis: Expert opinions.

W. Ageno, D. Jiménez, S. Middeldorp, 2021, Thrombosis and haemostasis.

Thrombo-Embolic Events in Cancer Patients with Impaired Renal Function

J. Canon, A. Awada, J. Baurain, 2014 .

Triple positive profile in antiphospholipid syndrome: prognosis, relapse and management from a retrospective multicentre study

J. Boffa, E. Rondeau, A. Mékinian, 2023, RMD Open.

Calpastatin controls polymicrobial sepsis by limiting procoagulant microparticle release.

E. Letavernier, J. Haymann, R. Star, 2012, American journal of respiratory and critical care medicine.

Urologic Surgery

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Cost-Effectiveness of Prevention and Treatment of VTE

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

The Modified APC Resistance Test in the Presence of Factor V Deficient Plasma Can Be Used in Patients without Oral Anticoagulant

M. Trossaërt, M. Horellou, I. Elalamy, 1996, Thrombosis and Haemostasis.

COVID-19 PANDEMIC UPDATES AND PERSPECTIVES. NEED FOR AN INTEGRATED AND EQUITABLE APPROACH.

V. Maréchal, A. Falanga, N. Jabeen, 2021, Thrombosis and haemostasis.

Association between Radiotherapy and Risk of Cancer Associated Venous Thromboembolism: A Sub-Analysis of the COMPASS—CAT Study

L. Jara-Palomares, S. Temraz, M. Charafeddine, 2021, Cancers.

Coronavirus disease (COVID-19) and disseminated intravascular coagulation syndrome

V. B. Nemirovskiy, A. Makatsariya, J. Khizroeva, 2020 .

aggregation MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet Platelet release of trimolecular complex components

I. Elalamy, G. Nguyen, J. Sraer, 2010 .

In vitro effect of melagatran and lepirudin on clot-bound thrombin.

M. Samama, I. Elalamy, J. Lebrazi, 2003, Thrombosis Research.

Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19

M. Dimopoulos, T. Psaltopoulou, E. Terpos, 2020, Hämostaseologie.

Venous thromboembolism risk, prophylaxis and management in cancer patients with COVID-19: An unmet medical need

H. Abdel-Razeq, G. Agnelli, A. Falanga, 2022, Thrombosis Update.

A fatal low‐molecular‐weight heparin‐associated thrombocytopenia after hip surgery: possible usefulness of PF4‐heparin ELISA test

M. Samama, I. Elalamy, J. Marie, 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

M. Dimopoulos, T. Psaltopoulou, E. Kastritis, 2018, Blood Cancer Journal.

Tumor Genetics Are Thrombogenic

F. Scotté, I. Mahé, I. Elalamy, 2023, JACC. CardioOncology.

Comparison of the DOAC Dipstick Test on Urine Samples With Chromogenic Substrate Methods on Plasma Samples in Outpatients Treated With Direct Oral Anticoagulants

S. Hetjens, J. Fareed, I. Elalamy, 2023, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Thrombose d’un circuit de circulation extracorporelle sous danaparoïde sodique à la phase aiguë d’une thrombopénie induite par l’héparine de type II en dépit d’une hypocoagulation recommandée

I. Elalamy, L. Salmi, R. Houel, 2006 .

Tests de coagulation et Xarelto® : indications sans recommandations

I. Elalamy, M. Solignac, 2011 .

[Resistance to activated protein C in venous thromboembolic complications. Incidence and clinical manifestations].

M. Trossaërt, I. Elalamy, J. Conard, 1995, Presse medicale.

Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19

T. Psaltopoulou, E. Terpos, G. Pialoux, 2020, Thrombosis and Haemostasis.

Primary prevention of cancer-associated venous thrombosis: Rationale and challenges in clinical practice.

A. Cohen-Solal, O. Hanon, J. Spano, 2023, Current research in translational medicine.

Usual risk factors do not predict venous thromboembolism in newly diagnosed myeloma treated with immunomodulatory drugs

S. Laporte, X. Leleu, C. Chapelle, 2016, American journal of hematology.

Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma

F. Depasse, M. Samama, Meyer M Samama, 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Thrombotic storm, hemostasis disorders and thromboinflammation in COVID-19

J. Gris, E. Grandone, A. Makatsariya, 2020, Obstetrics, Gynecology and Reproduction.

Signal transduction involved in the platelet adenylate cyclase sensitization associated with PGH2/TxA2 receptor desensitization

B. Boris Vargaftig, I. Elalamy, S. Emadi, 1997, British journal of haematology.

Laboratory monitoring of COVID-19 patients and importance of coagulopathy markers

J. Gris, A. Makatsariya, M. Tretyakova, 2020 .

Platelets, thrombo-inflammation and cancer

V. Galkin, J. Khizroeva, M. Tretyakova, 2021, Obstetrics, Gynecology and Reproduction.

Combined Modalities in Surgical Patients

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Extracellular neutrophil traps (NETs) in the pathogenesis of thrombosis and thromboinflammation

J. Gris, E. Grandone, A. Makatsariya, 2021 .

TNF-alpha, inefficient by itself, potentiates IL-1beta-induced PGHS-2 expression in human pulmonary microvascular endothelial cells: requirement of NF-kappaB and p38 MAPK pathways.

C. Werts, I. Elalamy, C. Jacquemin, 2002, British journal of pharmacology.

[Pathogenesis of venous thromboembolic disease in cancer].

I. Elalamy, G. Gerotziafas, M. Hatmi, 2008, Pathologie-biologie.

Platelet function analyser‐100 testing and primary haemostasis analysis

I. Elalamy, M. Hatmi, 2006, British journal of haematology.

The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles

M. Maier‐Redelsperger, R. Girot, F. Lionnet, 2012, Thrombosis and Haemostasis.

Thrombin Generation Profile in Patients With Steady State Peripheral Arterial Disease

M. Catalano, I. Elalamy, M. Kozak, 2018, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Effect of low molecular weight heparins and fondaparinux upon thrombin generation triggered by human pancreatic cancer cells BXPC3.

J. Bernaudin, J. Lotz, J. Fareed, 2014, Current vascular pharmacology.

Prevention and treatment of venous thromboembolism

G. Raskob, A. Nicolaides, M. Griffin, 1990 .

The GPIIIa PlA polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin.

I. Elalamy, Z. Dridi, H. Gamra, 2010, Thrombosis research.